Latest Antibody Stories
SAN DIEGO, Aug. 8, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately held therapeutic antibody company, today announced the addition of Andrew J. McKnight, Ph.D. as Senior Director, Target Biology. Dr. McKnight comes to AnaptysBio with extensive experience in the design and development of novel therapeutic antibodies across a variety of therapeutic areas. Working together with David J. King, Ph.D., AnaptysBio's chief scientific officer, Dr. McKnight will be leading the...
The deadliest form of malaria is caused the protozoan Plasmodium falciparum. During its life-cycle in human blood, the parasite P. falciparum expresses unique proteins on the surface on infected blood cells. Antibodies to these proteins are associated with protection from malaria, however, the identity of surface protein(s) that elicit the strongest immune response is unknown. Dr. James Beeson and colleagues at the Walter and Eliza Hall Institute of Medical Research in Victoria, Australia...
FARMINGTON, Conn., Aug. 1, 2012 /PRNewswire-iReach/ -- Global Information Inc is pleased to announce limited available early bird discounted registration for three important international healthcare and biotechnology conferences: (Photo: http://photos.prnewswire.com/prnh/20120801/CG50305) PEGS Europe - Protein & Antibody Engineering Summit 2012 November 6-8, 2012 | Vienna, Austria The Fourth Annual Protein & Antibody Engineering Summit (PEGS Europe) presents an exciting opportunity...
LEBANON, N.H. and CAMBRIDGE, Mass., Aug. 1, 2012 /PRNewswire/ -- Adimab, LLC, the technology leader in the discovery and optimization of fully human therapeutic antibodies, and Mersana Therapeutics, Inc., a next-generation antibody-drug conjugate (ADC) company, today announced the initiation of a joint effort to offer integrated antibody discovery and ADC technologies. The alliance is built to offer pharmaceutical companies seamless access to Adimab's world-class antibodies that...
FORT LEE, N.J., July 31, 2012 /PRNewswire/ -- Effective today, The Kedrion Group [www.kedrion.com] completed acquisition of the RhoGAM(®) line of products [www.RhoGAM.com] from Ortho-Clinical Diagnostics, Inc. (OCD). The acquisition includes the transfer of the Rho(D) Immune Globulin (Human) RhoGAM(®) Ultra-Filtered PLUS and Rho(D) Immune Globulin (Human) MICRhoGAM(®) Ultra-Filtered PLUS products as well as Somerset Laboratories, Inc., a wholly owned subsidiary of Ortho Clinical...
CAMBRIDGE, Mass., July 31, 2012 /PRNewswire/ -- Mersana Therapeutics, Inc., a biopharmaceutical company developing its Fleximer(®) antibody-drug conjugate (ADC) platform and pipeline of small molecule Fleximer conjugates, announced today that it has closed a $27 million Series A-1 financing led by new investor New Enterprise Associates (NEA). Participation in the round also included new investor Pfizer Venture Investments and existing investors Fidelity Biosciences, ProQuest...
SEATTLE, July 31, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that it believes it has identified the proteins that activate the alternative pathway of the complement system, an important part of the immune system. The work was led by the Company's collaborator, Professor Wilhelm Schwaeble of the University of Leicester, and Omeros controls the worldwide exclusive rights to this discovery. The complement system plays an important role in the inflammatory...
The IgNS National Conference represents a major new educational initiative to develop and sustain the advancement of knowledge, education and practice of nursing in the field of immunoglobulin therapy. The Orlando conference will feature in-depth educational sessions, hands-on practical workshops, industry-sponsored symposia, and an exhibit hall featuring the top Immunoglobulin (Ig)-related companies in the country. Los Angeles, CA (PRWEB) July 30, 2012 Immunoglobulin nurses will gather...
CRANBURY, N.J., July 30, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today a collaboration agreement with XOMA Corporation to develop novel biotherapeutics based on engineering single-chain variable fragments (scFv) into a bi-specific antibody scaffold. Through the partnership, Oncobiologics will utilize XOMA's ADAPT(TM) fully human antibody technology platform as a key component of its drug discovery program. Oncobiologics has selected clinically validated targets that will be...
PLYMOUTH, Minn., July 24, 2012 /PRNewswire/ --The Jeffrey Modell Foundation (JMF), in partnership with CSL Behring, has designated the Midwest Immunology Clinic in Plymouth, Minnesota as a Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies (PI). The Center is headed by Ralph Shapiro, M.D. and is devoted to the diagnosis, treatment and care of people who have PI and autoimmune disorders. "This is a very exciting day for Midwest Immunology Clinic," said Dr. Shapiro. "We...
